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Background: The aims of this study were to confirm the presence of OmpK35 and OmpK36 
in extended-spectrum beta-lactamase-producing and nonextended-spectrum beta-lactamase-
producing Klebsiella pneumoniae and to determine the relationship between porin expression 
and resistance to third-generation cephalosporins.
Methods: Fifty-two K. pneumoniae isolates were obtained and analyzed for extended-spectrum 
beta-lactamase and for OmpK35 and OmpK36.
Results: Twenty-two (42.3%) isolates of K. pneumoniae were extended-spectrum beta-lactamase 
producers. The OmpK35 profile in K. pneumoniae producing extended-spectrum beta-lactamase 
showed the presence of porin protein in ceftazidime-sensitive K. pneumoniae (six isolates), and 
the OmpK36 profile in K. pneumoniae producing extended-spectrum beta-lactamase revealed 
isolates sensitive to cefotaxime (n = 8) and ceftriaxone (n = 6). All nonextended-spectrum 
beta-lactamase-producing K. pneumoniae showed the presence of OmpK35 and OmpK36 
porin proteins.
Conclusion: The presence of OmpK35 is mostly related to ceftazidime susceptibility and less 
to cefotaxime and ceftriaxone susceptibility, while OmpK36 expression is seen more often in 
cefotaxime-sensitive isolates. OmpK35 and OmpK36 indicate nonextended-spectrum beta-
lactamase producing strains, and their presence is important when selecting an antimicrobial 
agent.
Keywords: Klebsiella pneumoniae, extended-spectrum beta-lactamase producing strains, 
porin expression
Introduction
Because of development of plasmids producing extended-spectrum beta-lactamase 
(ESBL), Klebsiella pneumoniae is resistant to a number of broad-spectrum antibiotics, 
including cephalosporins. Therefore, treatment of infections caused by bacteria 
producing ESBL is problematic.1,2 The first report of ESBL-producing K. pneumoniae 
occurred in 1983 in Germany.1 Majiduddin et al then classified these enzymes based 
on their sequence similarity and catalytic mechanism into four main groups, ie, classes 
A, B, C, and D.3
K. pneumoniae produces two major porins, OmpK35 and OmpK36, and the 
quiescent porin OmpK37. Details on OmpK36 and OmpK37 have been reported 
previously.4 Most clinical isolates of K. pneumoniae lacking ESBL express both 
OmpK35 and OmpK36 porins, while most ESBL-expressing K. pneumoniae clinical 
isolates produce only OmpK36.5 Until now, the few clinical isolates lacking both 
OmpK35 and OmpK36 have been ESBL-producing strains.6Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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Loss of OmpK36 is associated with cefoxitin resistance 
and increased resistance to oxyimino and zwitterionic 
cephalosporins in strains producing ESBL and to carbapenem 
resistance in strains producing plasmid-mediated AmpC-type 
beta-lactamase.7 Loss of OmpK36 also results in a moderate 
increase in fluoroquinolone resistance in strains with 
altered topoisomerases and/or active efflux of quinolones. 
Preliminary results indicate that OmpK35 allows efficient 
penetration of cefoxitin, cefotaxime, and carbapenem, but 
there has been some controversy on the role of this porin 
in cephalosporin penetration in K. pneumoniae.8 Detailed 
studies of the importance of OmpK35 in antimicrobial 
resistance are lacking. The aims of this study were to 
determine the presence of OmpK35 and OmpK36 in ESBL-
producing and non-ESBL-producing K. pneumoniae and to 
find a relationship between porin expression and resistance 
to third-generation cephalosporins.
Materials and methods
Bacterial strains
Fifty-two K. pneumoniae isolates were obtained from March 
2010 to August 2010 at Milad Hospital, Tehran, Iran. All 
isolates were from patients with urinary tract infection. The 
sensitivity of the isolates to third-generation cephalosporins 
(ceftazidime, cefotaxime, ceftriaxone) and to second-
generation cephalosporin (cefoxitin) and a carbapenem 
(imipenem) was determined by the disc diffusion method 
(each antibiotic 30 µg/disc).9 The results were interpreted as 
per National Committee for Clinical Laboratory Standards 
recommendations.6 Escherichia coli ATCC 25922 was used 
as a quality control.
eSBL detection by double-disc  
synergy test
Isolates with resistance to or decreased susceptibility (inter-
mediate by National Committee for Clinical Laboratory Stan-
dards criteria) to any of the third-generation   cephalosporins 
were subjected to the standard double-disc synergy test.10 
Because the isolates in the present study were found to be 
resistant to at least one of the three third-generation cepha-
losporins, they were all tested for ESBL production using 
this test.
Analysis of outer membrane proteins
Bacterial cells were grown in nutrient beef extract broth 3 g 
and Proteose Peptone 3.5 g (both from Difco Laboratories 
Inc, Detroit, MI) in 1 L of distilled water to increase OmpK35 
expression. Cells in the logarithmic phase were lysed by 
sonication and the cell membranes were recovered by ultra-
centrifugation. Outer membrane proteins were obtained 
after treatment of cell membranes with sodium lauryl sar-
cosinate (Sigma-Aldrich, St Louis, MO) and subsequent 
ultracentrifugation. Outer membrane protein profiles were 
determined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis using 11% acrylamide, 0.5% bis-acrylamide, 
and 0.1% sodium dodecyl sulfate in the running gel.11
Statistical analysis
Chi-square testing using SPSS version 16 (SPSS Inc, Chi-
cago, IL) was undertaken with appropriate correction for the 
observation and for the significance between ESBL production 
and Ompk35/36 expression P  0.05 was considered to be 
statistically significant.
Results
Phenotypic ESBL screening and confirmation using the 
double-disc synergy test showed that 22 (42.3%) isolates 
of K. pneumoniae were ESBL producers and 30 (57.7%) 
isolates were non-ESBL producers. Of the 22 K.   pneumoniae 
isolates, 16 (72%), 14 (63.6%), and 16 (72%) isolates 
were resistant to ceftazidime, cefotaxime, and ceftriaxone, 
respectively.
The OmpK35 profile in K. pneumoniae producing 
ESBL showed the presence of porin protein in six (27.3%) 
ceftazidime-sensitive K. pneumoniae isolates. OmpK35 was 
not expressed in cefotaxime-susceptible isolates but was 
expressed in four (18.2%) ceftriaxone-sensitive isolates. 
A significant difference was found between the antimicrobial 
panels for ceftazidime (P , 0.01), cefotaxime (P , 0.003), 
and ceftriaxone (P , 0.013) and OmpK35 in ESBL-positive 
strains.
The OmpK36 profile in K. pneumoniae producing ESBL 
was identified in all isolates sensitive to cefotaxime (27.3%) 
and ceftriaxone (36.4%) but was only seen in two (9%) 
K. pneumoniae isolates sensitive to ceftazidime. No sig-
nificant difference was observed between OmpK36 and the 
antimicrobial panel for ceftazidime (P , 0.13), while a sig-
nificant difference occurred between the antimicrobial panel 
of ceftriaxone (P , 0.017) and cefotaxime (P , 0.003) with 
OmpK36 (Table 1). All non-ESBL-producing K. pneumoniae 
showed OmpK35 and OmpK36 protein expression.
Discussion
OmpK35 and OmpK36 provide a channel enabling a 
wide range of antibiotics to penetrate the cell wall of 
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Table 1 Third-generation cephalosporins pattern and presence of OmpK in Klebsiella pneumoniae producing extended-spectrum   
beta-lactamase
K. pneumoniae Ceftazidime Cefotaxime Ceftriaxone OmpK35 OmpK36
K1 S r S P P
K2 S r S P P
K3 S r r P n
K4 S r r P n
K5 S r r P n
K6 S r r P n
K7 r S r n P
K8 r S r n P
K9 r S r n P
K10 r r S P P
K11 r S S n P
K12 r S r n P
K13 r S r n P
K14 r S r n P
K15 r S r n P
K16 r r r n n
K17 r r r n n
K18 r r r n n
K19 r r r n n
K20 r r r n n
K21 r r S P P
K22 r r S n P
Abbreviations: r, resistance; S, sensitive; P, positive; n, negative.
and ectopic expression of OmpK35 or OmpK36 in a strain 
lacking both OmpK35 and OmpK36.12 Porins play a crucial 
role in the interaction between bacteria and the environ-
ment. In addition, and probably as a consequence, porins 
are present in large amounts in the outer membrane of 
  Gram-negative bacteria. Since the identification of the 
major porins, OmpC and OmpF, in E. coli, a large number 
of OmpC-type or OmpF-type porins have been described 
in other enterobacterial species. We have reported the 
existence of two major porins, OmpK36 and OmpK35, in 
K. pneumoniae. These porins are homologous to OmpC 
and OmpF, and are expressed in large amounts in most 
K. pneumoniae clinical isolates independent of the isola-
tion source.5 We have focused our attention on the role of 
these porins in penetration of the cell wall by antibiotics. 
As has been reported for other species, the absence of porin 
is an important cause of resistance to some antimicrobials, 
particularly beta-lactam antibiotics.13
As a result of these investigations, we isolated clinical 
strains resistant to most of the beta-lactam antibiotics cur-
rently used to treat K. pneumoniae infections. These isolates 
had a characteristic in common, ie, they simultaneously 
lacked expression of porins, OmpK35 and OmpK36. Most 
clinical isolates of K. pneumoniae lacking ESBL express both 
OmpK35 and OmpK36 porins. Our results indicate that the 
presence of OmpK35 is most related to ceftazidime suscep-
tibility and less to cefotaxime and ceftriaxone susceptibility, 
while OmpK36 expression is more commonly observed in 
cefotaxime-sensitive isolates.
Porins are important for bacterial survival because of 
their role in the exchange of substances, including nutrients 
and toxic metabolites. Previous studies have shown that 
few clinical ESBL-producing K. pneumoniae isolates lack 
both OmpK35 and OmpK36, although strains lacking both 
porins exhibit higher antibiotic resistance than strains that 
express only one or both porins.14 These results suggest that 
OmpK35 and OmpK36 play dual roles in K. pneumoniae 
infection.
In conclusion, the results indicate that the presence 
of OmpK35 is mostly related to ceftazidime susceptibil-
ity and less to cefotaxime and ceftriaxone susceptibility, 
while OmpK36 expression is more commonly observed in 
cefotaxime-sensitive isolates. Our results also show that 
OmpK35 and OmpK36 are found in non-ESBL-producing 
strains, and their presence is important when selecting an 
antimicrobial agent.
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